Tag: janssen
Data from new VOYAGER PAD reinforce benefit of XARELTO (rivaroxaban) plus...
An analysis showed benefit of XARELTO plus aspirin in reducing thrombotic hospitalisations for peripheral arterial disease (PAD) patients with and without chronic kidney disease...
FDA approves expanded PAD indication for Xarelto plus aspirin to include...
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the US Food and Drug Administration (FDA) has approved an expanded peripheral arterial...
Janssen submits application to US FDA for new indication to expand...
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the US Food and...
FDA approves new 10mg dosing for rivaroxaban to reduce continued risk...
Janssen Pharmaceuticals has announced that the FDA has approved the 10mg once-daily dose of rivaroxaban (Xarelto) for reducing the continued risk for recurrent venous...
